Johnson & Johnson Has Potential To Drive Its Pharma And MedTech Franchises, Says Bullish Analyst
Portfolio Pulse from Priya Nigam
Shares of Johnson & Johnson (NYSE:JNJ) recovered slightly after a previous session's drop. RBC Capital Markets analyst Shagun Singh initiated coverage of the company with an Outperform rating and a price target of $178. Singh believes that the company is uniquely positioned with Pharma and MedTech under one umbrella and has unlocked potential with the separation of its Consumer Health segment. He also expressed optimism around the MedTech franchise.
October 05, 2023 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's shares recovered slightly after a drop. The company received an Outperform rating and a price target of $178 from RBC Capital Markets analyst Shagun Singh.
The positive outlook from RBC Capital Markets analyst Shagun Singh, including an Outperform rating and a price target of $178, is likely to boost investor confidence in Johnson & Johnson, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100